Faecal Transplantation, Pro- and Prebiotics in Parkinson's Disease; Hope or Hype?

Area of Science:

• Gastroenterology
• Neurology
• Microbiology

Background:

• Faecal microbiome transplantation (FMT) is a promising therapeutic approach due to its simple administration and mild adverse effect profile.
• The broad microbial mixture in FMT may offer benefits, but specific microbiome changes required for therapeutic effects remain unknown.
• Current clinical data on FMT in Parkinson's disease (PD) is scarce, with limited evidence suggesting potential benefits for severe constipation in PD patients.

Purpose of the Study:

• To evaluate the current clinical data supporting the use of FMT in Parkinson's disease.
• To assess the efficacy and safety of FMT and probiotic treatments in PD patients.
• To identify knowledge gaps and areas requiring further research in microbiome-based therapies for PD.

Main Methods:

• Review of existing clinical data and literature on FMT and probiotic interventions in Parkinson's disease.
• Analysis of the current understanding of microbiome alterations in PD.
• Identification of safety concerns and efficacy data for FMT and probiotics in PD.

Main Results:

• Limited clinical data exists for FMT in PD, with only anecdotal evidence for constipation relief.
• Probiotic species like Lactobacillus and Bifidobacterium have shown efficacy in treating constipation in PD patients over 4-12 weeks.
• No robust clinical data supports the use of probiotics for motor symptoms or PD progression.

Conclusions:

• FMT in PD remains a 'black box' with numerous unanswered questions regarding efficacy and safety.
• While probiotics can alleviate constipation in PD, their impact on motor symptoms and disease progression is not established.
• Further rigorous clinical trials are necessary to determine the appropriate use, target populations, and expected clinical effects of FMT and probiotics in Parkinson's disease.